Aspirin in Colorectal Cancer Liver Metastases (ASAC)

  • End date
    Feb 28, 2026
  • participants needed
  • sponsor
    Oslo University Hospital
Updated on 29 April 2022
liver metastasis
primary tumor


The ASAC trial is a Scandinavian, multi-center, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose acetylsalicylic acid (ASA) can improve disease free survival in patients treated with resection for colorectal cancer liver metastases (CRCLM).

Several studies have shown beneficial effect of ASA on primary prevention of CRC and the investigators group and others have shown a potential association of ASA also taken after the diagnosis on CRC survival in registry-based studies (secondary prevention). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo for a period of 3 years or till disease recurrence. The patients will be treated and followed up according to standard of care and the National Guidelines.

The ASAC trial will be the first clinical interventional trial to assess the beneficial role of ASA in recurrence of CRC liver metastases and survival. ASA is an inexpensive, well tolerated, and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRC liver metastases if the study shows a beneficial effect. This trial will also investigate the effect of ASA as adjuvant treatment on Health-related Quality of Life and the cost-effectiveness.

Condition Colorectal Cancer Liver Metastases, Colorectal Cancer, Liver Metastases
Treatment Acetylsalicylic acid, Placebo Oral Tablet
Clinical Study IdentifierNCT03326791
SponsorOslo University Hospital
Last Modified on29 April 2022


Yes No Not Sure

Inclusion Criteria

First time CRCLM (synchronous or metachronous)
Recurrence of CRCLM (not previously included in this trial)
In synchronous CRCLM and "Liver first" approach, the primary tumor must be resected within 6 weeks after the liver
Macroscopic (surgical) free resection margins (R0 or R1 resection)
Must be ambulatory with a performance status Eastern Cooperative Oncology Group (ECOG) 0-2
Must be at least 18 years of age
Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to International Conference on Harmonization - Good Clinical Practice (ICH GCP), and national/local regulations

Exclusion Criteria

Concomitant use of ASA or other anticoagulants or platelet inhibitors such as warfarin or clopidogrel
Ongoing regular use of corticosteroids or NSAIDs
Inherited or acquired coagulopathy (haemophilia)
Blood platelets (thrombocytes) < 100 x 10^9/L
Severe heart failure (classified as New York Heart Association (NYHA) class >III)
Severe kidney failure >Stage 3b
CRCLM previously treated with radiofrequency or microwave ablation technique
Pregnancy or breastfeeding. For women in childbearing age there will be pregnancy test at monthly intervals (urine human chorionic gonadotropin (HCG) pregnancy tests (for home testing) will be given to the patients for monthly tests and the patient will self-report the results at each control). Furthermore, highly effective contraceptives will be required
Childbearing potential without proper contraceptive measures such as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device to avoid pregnancy for the entire study period
Liver cirrhosis with a Child-Pugh score >B7
Contraindication listed on the Summary of Product Characteristics (SmPC) of Trombyl: Hypersensitivity/allergies to ASA, Thrombocytopenia, Previous severe gastrointestinal haemorrhage/peptic ulcer due to ASA/NSAID, Active peptic ulcer, Haemophilia, Liver cirrhosis, Severe congestive heart failure
Need to use concomitant medications contraindicated according to SmPC of Trombyl
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note